Lombard Odier Asset Management (Switzerland)’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.07M Buy
83,569
+18,900
+29% +$1.1M 0.19% 116
2025
Q4
$3.49M Sell
64,669
-11,200
-15% -$539K 0.15% 145
2025
Q3
$3.42M Buy
75,869
+4,868
+7% +$227K 0.15% 131
2025
Q2
$3.29M Buy
71,001
+1,902
+3% +$93.4K 0.17% 131
2025
Q1
$4.21M Buy
69,099
+9,153
+15% +$534K 0.24% 106
2024
Q4
$3.39M Buy
59,946
+5,557
+10% +$310K 0.25% 107
2024
Q3
$2.81M Buy
54,389
+6,975
+15% +$327K 0.24% 115
2024
Q2
$1.97M Sell
47,414
-11,913
-20% -$533K 0.2% 110
2024
Q1
$3.22M Buy
59,327
+31,418
+113% +$1.6M 0.23% 116
2023
Q4
$1.43M Buy
27,909
+10,316
+59% +$542K 0.19% 108
2023
Q3
$1.02M Sell
17,593
-1,548
-8% -$94.8K 0.17% 110
2023
Q2
$1.22M Sell
19,141
-215,121
-92% -$14.4M 0.17% 102
2023
Q1
$16.2M Sell
234,262
-8,971
-4% -$633K 1.42% 15
2022
Q4
$17.5M Sell
243,233
-45,161
-16% -$3.41M 1.4% 21
2022
Q3
$20.5M Sell
288,394
-5,237
-2% -$380K 1.74% 12
2022
Q2
$22.6M Sell
293,631
-64,667
-18% -$4.93M 1.91% 7
2022
Q1
$26.2M Buy
358,298
+337,756
+1,644% +$22.7M 2.05% 14
2021
Q4
$1.28M Sell
20,542
-4,873
-19% -$286K 0.08% 122
2021
Q3
$1.41M Sell
25,415
-393
-2% -$25.9K 0.09% 126
2021
Q2
$1.72M Buy
25,808
+6,401
+33% +$417K 0.09% 143
2021
Q1
$1.23M Sell
19,407
-3,495
-15% -$217K 0.08% 138
2020
Q4
$1.42M Sell
22,902
-21,917
-49% -$1.35M 0.16% 70
2020
Q3
$2.7M Buy
44,819
+16,492
+58% +$993K 0.28% 64
2020
Q2
$1.67M Sell
28,327
-21,315
-43% -$1.27M 0.26% 69
2020
Q1
$2.77M Sell
49,642
-23,358
-32% -$1.43M 0.37% 49
2019
Q4
$4.69M Buy
73,000
+28,367
+64% +$1.62M 0.44% 53
2019
Q3
$2.26M Sell
44,633
-7,221
-14% -$339K 0.24% 76
2019
Q2
$2.35M Buy
51,854
+15,785
+44% +$735K 0.24% 85
2019
Q1
$1.72M Buy
36,069
+31,113
+628% +$1.55M 0.17% 102
2018
Q4
$258K Sell
4,956
-7,119
-59% -$382K 0.03% 296
2018
Q3
$750K Buy
12,075
+4,559
+61% +$271K 0.07% 204
2018
Q2
$416K Sell
7,516
-3,779
-33% -$204K 0.04% 230
2018
Q1
$714K Buy
11,295
+4,792
+74% +$308K 0.07% 228
2017
Q4
$399K Hold
6,503
0.04% 255
2017
Q3
$415K Hold
6,503
0.04% 255
2017
Q2
$362K Hold
6,503
0.04% 278
2017
Q1
$354K Buy
+6,503
New +$357K 0.04% 285
2016
Q3
Sell
-145,118
Closed -$10.7M 125
2016
Q2
$10.7M Buy
145,118
+141,149
+3,556% +$9.97M 1.45% 21
2016
Q1
$254K Hold
3,969
0.03% 231
2015
Q4
$276K Sell
3,969
-3,786
-49% -$250K 0.03% 229
2015
Q3
$461K Sell
7,755
-7,458
-49% -$473K 0.04% 179
2015
Q2
$1.01M Sell
15,213
-3,675
-19% -$242K 0.08% 129
2015
Q1
$1.23M Sell
18,888
-9,377
-33% -$587K 0.14% 108
2014
Q4
$1.68M Sell
28,265
-431,223
-94% -$24.3M 0.18% 106
2014
Q3
$23.6M Buy
459,488
+441,191
+2,411% +$22M 0.61% 33
2014
Q2
$884K Buy
+18,297
New +$902K 0.1% 120

Other funds holding BMY

Lombard Odier Asset Management (Switzerland)'s BMY Position: Q1 2026 in Review

Lombard Odier Asset Management (Switzerland) increased its Bristol-Myers Squibb (BMY) stake by 29% in Q1 2026, buying an estimated $1.1M and bringing the position to 83,569 shares worth $5.07M. The position accounts for 0.19% of the portfolio, ranked #116.

Lombard Odier Asset Management (Switzerland) first reported a position in BMY in Q2 2014 and has held it in 46 quarters since. The position peaked at $26.2M in Q1 2022. 2,526 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Lombard Odier Asset Management (Switzerland) held 83,569 shares of Bristol-Myers Squibb worth $5.07M as of Q1 2026.
  • Lombard Odier Asset Management (Switzerland) bought 18,900 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.1M.
  • Bristol-Myers Squibb made up 0.19% of Lombard Odier Asset Management (Switzerland)'s portfolio in Q1 2026, its #116 holding.
  • Lombard Odier Asset Management (Switzerland) first reported a position in Bristol-Myers Squibb in Q2 2014 and has held it in 46 quarters since.
  • Lombard Odier Asset Management (Switzerland)'s Bristol-Myers Squibb position peaked at $26.2M in Q1 2022.
  • 2,526 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q1 2026, filed 15 May 2026.